These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22123124)

  • 1. Effect of histidine-tag and R457H and E580Q mutations on catalytic activity of recombinant human cytochrome P450 oxidoreductase.
    Niwa T; Minami K; Katagiri M
    Drug Metab Pharmacokinet; 2012; 27(1):150-4. PubMed ID: 22123124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.
    Jin Y; Chen M; Penning TM; Miller WL
    Biochem J; 2015 May; 468(1):25-31. PubMed ID: 25728647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.
    Agrawal V; Huang N; Miller WL
    Pharmacogenet Genomics; 2008 Jul; 18(7):569-76. PubMed ID: 18551037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
    Flück CE; Nicolo C; Pandey AV
    Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-yield expression of a catalytically active membrane-bound protein: human P450 oxidoreductase.
    Sandee D; Miller WL
    Endocrinology; 2011 Jul; 152(7):2904-8. PubMed ID: 21586563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P450 oxidoreductase deficiency: a new disorder of steroidogenesis.
    Miller WL; Huang N; Pandey AV; Flück CE; Agrawal V
    Ann N Y Acad Sci; 2005 Dec; 1061():100-8. PubMed ID: 16467261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Purification of Recombinant Rat NADPH-P450 Reductase by Using a Hexahistidine-Tag.
    Park HG; Lim YR; Han S; Jeong D; Kim D
    J Microbiol Biotechnol; 2017 May; 27(5):983-989. PubMed ID: 28274101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electron transfer in flavocytochrome P450 BM3: kinetics of flavin reduction and oxidation, the role of cysteine 999, and relationships with mammalian cytochrome P450 reductase.
    Roitel O; Scrutton NS; Munro AW
    Biochemistry; 2003 Sep; 42(36):10809-21. PubMed ID: 12962506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trp-676 facilitates nicotinamide coenzyme exchange in the reductive half-reaction of human cytochrome P450 reductase: properties of the soluble W676H and W676A mutant reductases.
    Gutierrez A; Doehr O; Paine M; Wolf CR; Scrutton NS; Roberts GC
    Biochemistry; 2000 Dec; 39(51):15990-9. PubMed ID: 11123926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P450 oxidoreductase: genotyping, expression, purification of recombinant protein, and activity assessments of wild-type and mutant protein.
    Agrawal V; Miller WL
    Methods Mol Biol; 2013; 987():225-37. PubMed ID: 23475681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.
    Subramanian M; Agrawal V; Sandee D; Tam HK; Miller WL; Tracy TS
    Pharmacogenet Genomics; 2012 Aug; 22(8):590-7. PubMed ID: 22547083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
    Burkhard FZ; Parween S; Udhane SS; Flück CE; Pandey AV
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):38-50. PubMed ID: 27068427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.
    Huang N; Pandey AV; Agrawal V; Reardon W; Lapunzina PD; Mowat D; Jabs EW; Van Vliet G; Sack J; Flück CE; Miller WL
    Am J Hum Genet; 2005 May; 76(5):729-49. PubMed ID: 15793702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic studies on the reductive half-reaction of NADPH-cytochrome P450 oxidoreductase.
    Shen AL; Sem DS; Kasper CB
    J Biol Chem; 1999 Feb; 274(9):5391-8. PubMed ID: 10026149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
    Sandee D; Morrissey K; Agrawal V; Tam HK; Kramer MA; Tracy TS; Giacomini KM; Miller WL
    Pharmacogenet Genomics; 2010 Nov; 20(11):677-86. PubMed ID: 20940534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase.
    Flück CE; Pandey AV
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):64-70. PubMed ID: 27032764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic mechanism of cytochrome P450 reductase from the house fly (Musca domestica).
    Murataliev MB; Ariño A; Guzov VM; Feyereisen R
    Insect Biochem Mol Biol; 1999 Mar; 29(3):233-42. PubMed ID: 10319436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proximal FAD histidine residue influences interflavin electron transfer in cytochrome P450 reductase and methionine synthase reductase.
    Meints CE; Parke SM; Wolthers KR
    Arch Biochem Biophys; 2014 Apr; 547():18-26. PubMed ID: 24589657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase.
    Pandey AV; Kempná P; Hofer G; Mullis PE; Flück CE
    Mol Endocrinol; 2007 Oct; 21(10):2579-95. PubMed ID: 17595315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.
    Miller WL
    Sci Signal; 2012 Oct; 5(247):pt11. PubMed ID: 23092891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.